Clinical Trials
12 trialsNCT06308263 2026-04-23
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT03309150 2024-11-29
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04095273 2024-04-02
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
Phase 1 Completed
NCT03730142 2023-04-18
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1 Completed
NCT02684032 2022-07-27
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
Phase 1 Completed
NCT00726583 2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1 Completed
NCT01470209 2018-03-19
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Emory University
Phase 1 Completed
NCT01449370 2017-03-09
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Takeda
Phase 1 Completed
NCT02598570 2017-02-06
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
AbbVie
Phase 1 Completed